GlassScriptPhysician profile
Alkarim Tajuddin
NPI 1922069160
$35,666.63
in general payments reported to CMS, 2019-2025
63 companies · $5,291 in 2025
The $5,291 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,811 · 2020: $6,730 · 2021: $621 · 2022: $7,968 · 2023: $5,577 · 2024: $3,668 · 2025: $5,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,440 · Food and Beverage: $4,403 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Travel and Lodging: $653 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,440.00 |
| Food and Beverage | $4,403.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Travel and Lodging | $652.95 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,264.51 | 2019-2025 | Tagrisso, Imfinzi, Lynparza |
| Ipsen Biopharmaceuticals, INC | $3,879.33 | 2019 | |
| Celgene Corporation | $3,208.94 | 2019-2025 | Reblozyl, Pomalyst |
| Acceleron Pharma, INC. | $3,160.00 | 2020 | |
| Epizyme, INC. | $2,887.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $2,724.90 | 2019-2025 | |
| Abbvie INC. | $2,328.19 | 2019-2025 | Venclexta |
| Beigene USA, INC. | $2,073.76 | 2020-2023 | Brukinsa |
| Genzyme Corporation | $1,866.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,170.47 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Genentech USA, INC. | $728.39 | 2019-2025 | Tecentriq, Lunsumio, Phesgo |
| Pfizer INC. | $719.54 | 2019-2025 | |
| Exelixis INC. | $652.95 | 2024 | |
| Daiichi Sankyo INC. | $616.66 | 2020-2025 | Enhertu |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene, LTD. | $450.00 | 2020 | |
| Merck Sharp & Dohme LLC | $445.76 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $333.42 | 2019-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $311.48 | 2019-2024 | Alunbrig, Ninlaro, Iclusig |
| Janssen Biotech, INC. | $236.14 | 2019-2025 | Rybrevant, Balversa, Akeega |
| Gilead Sciences, INC. | $232.29 | 2021-2025 | Trodelvy |
| Eisai INC. | $195.56 | 2021-2025 | |
| Amgen INC. | $157.51 | 2019-2023 | Kyprolis, Lumakras |
| Astellas Pharma US INC | $124.64 | 2019-2024 | Xtandi, Padcev |
| Regeneron Healthcare Solutions, INC. | $118.19 | 2019-2025 | Lynozyfic, Libtayo |
| Seagen INC. | $107.37 | 2019-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $102.29 | 2022-2023 | Imbruvica |
| Incyte Corporation | $90.88 | 2023-2025 | Monjuvi, Jakafi |
| Adc Therapeutics America, INC. | $89.55 | 2024 | |
| Kite Pharma, INC. | $86.21 | 2023-2025 | Yescarta |
| Lilly USA, LLC | $83.37 | 2019-2024 | Jaypirca, Verzenio |
| Servier Pharmaceuticals LLC | $73.12 | 2022-2024 | |
| Array Biopharma INC | $72.79 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Emd Serono, INC. | $61.99 | 2019-2025 | Bavencio |
| Blueprint Medicines Corporation | $56.48 | 2023-2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $56.11 | 2019-2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $55.74 | 2023 | Avastin |
| Tersera Therapeutics LLC | $51.84 | 2022-2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $48.66 | 2021-2024 | Qinlock |
| Puma Biotechnology, INC. | $46.58 | 2022-2024 | |
| G1 Therapeutics, INC. | $45.74 | 2022-2023 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.12 | 2025 | |
| Pharmacosmos Therapeutics INC. | $44.05 | 2023-2024 | Cosela, Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $42.10 | 2019-2023 | |
| Advanced Accelerator Applications | $38.85 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $38.58 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $38.19 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $37.85 | 2025 | |
| Dendreon Pharmaceuticals LLC | $33.99 | 2024 | Provenge |
| Taiho Oncology, INC. | $30.89 | 2023-2025 | |
| Immunocore Limited | $28.97 | 2025 | Kimmtrak |
| Tempus Ai, INC | $28.69 | 2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $28.55 | 2025 | |
| Springworks Therapeutics, INC. | $28.09 | 2024 | Ogsiveo |
| Cti Biopharma Corp. | $24.60 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $24.39 | 2024 | Pyrukynd |
| Myriad Genetic Laboratories, INC. | $23.59 | 2024 | Myrisk |
| Mirati Therapeutics, INC. | $22.42 | 2024 | Krazati |
| Verastem, INC. | $21.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.88 | 2019 | |
| Genmab U.S., INC. | $18.29 | 2023 | Epkinly |
| Dova Pharmaceuticals | $17.89 | 2019 | |
| Immunogen, INC. | $14.04 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alkarim Tajuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.